INTERCEPT Blood System for Plasma

The risks of patient exposure to pathogenic agents that may cause transfusion-transmitted infectious disease (TTI) have not been eliminated by current blood safety measures. These risks remain inherent throughout the process of collecting, testing, manufacturing and distributing plasma for transfusion.

Repeated exposures to multiple donors during therapeutic plasma exchange (TPE) increases the risk of transfusion-transmitted infections.

The INTERCEPT™ Blood System for plasma is intended for the ex vivo pathogen inactivation of whole-blood derived plasma and apheresis plasma. The system is used to inactivate a broad spectrum of viruses, bacteria, protozoa and contaminating donor leukocytes in plasma components.

The introduction of INTERCEPT allows for a new cost model for blood component production. Conventional safety measures rely on adding new screening and testing methods as new threats emerge, entering a cycle of ever-increasing production costs. On the other hand, effective pathogen inactivation with INTERCEPT stops this cycle and can lead to cost savings with the removal of redundant safety measures.

The INTERCEPT processing system for plasma has been designed to treat single units of apheresis plasma or pools of two to three units of apheresis or whole-blood derived plasma. To maximise the efficiency of the INTERCEPT treatment process, the DONOpack plasma pooling kit enables the pooling of five whole-blood derived plasma units to produce six INTERCEPT-treated therapeutic plasma units.